Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.40 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.38 |
| ▸ | GBA1 | P04062 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.37 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.37 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.37 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | BCR | P11274 | 1/20 | 0.36 |
| ▸ | TNFRSF1A | P19438 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1067258 | 0.80 | HDAC2 (0.40) | HDAC2HDAC1HDAC3ABL1BCR | |
| SCHEMBL4791487 | 0.80 | GPR119 (0.46) | GPR119GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL196445 | 0.80 | HDAC1 (0.46) | GPR119GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL979206 | 0.79 | GPR119 (0.42) | GPR119NR4A2PAX8 | |
| SCHEMBL248463 | 0.79 | ALDH1A1 (0.41) | PAX8 | |
| Ammonia Solution, Strong SCHEMBL21835780 | 0.79 | HDAC1 (0.45) | GPR119GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL6880352 | 0.76 | MT-CO2 (0.46) | — | |
| SCHEMBL25218263 | 0.75 | ABCB1 (0.47) | GPR119GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL20163123 | 0.75 | TRPV1 (0.40) | PAX8ABL1BCR | |
| SCHEMBL2858258 | 0.73 | HDAC1 (0.42) | GPR119GABRA1GABRG2GABRB3GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673911-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2014-03-18 | — | — | US | disclosed |
| US-20140045850-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2014-02-13 | — | — | US | disclosed |
| US-8440830-B2 | Tetrahydro-fused pyridines as histone deacetylase inhibitors | 4SC AG (DE) | 2013-05-14 | — | — | US | disclosed |
| CN-101466670-B | Inhibitors of histone deacetylase | METHYLGENE INC | 2013-04-17 | — | — | CN | disclosed |
| EP-2197552-B1 | NOVEL TETRAHYDROFUSEDPYRIDINES AS HISTONE DEACETYLASE INHIBITORS | 4SC AG (DE) | 2012-11-21 | — | — | EP | disclosed |
| US-20120101147-A1 | INHIBITION OF HDAC2 TO PROMOTE MEMORY | THE GENERAL HOSPITAL CORPORATION D/B/A MASSACHUSETTS GENERAL HOSPITAL (US) | 2012-04-26 | — | — | US | disclosed |
| US-20110021771-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2011-01-27 | — | — | US | disclosed |
| US-20110021494-A1 | NOVEL TETRAHYDRO-FUSED PYRIDINES AS HISTONE DEACETYLASE INHIBITORS | 4SC AG (DE) | 2011-01-27 | — | — | US | disclosed |
| EP-2217588-A1 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2010-08-18 | — | — | EP | disclosed |
| EP-2197552-A2 | NOVEL TETRAHYDROFUSEDPYRIDINES AS HISTONE DEACETYLASE INHIBITORS | 4SC AG (DE) | 2010-06-23 | — | — | EP | disclosed |
| CN-101466670-A | Benzamide derivatives as inhibitors of histone deacetylase | METHYLGENE INC (CA) | 2009-06-24 | — | — | CN | disclosed |
| WO-2009055917-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2009-05-07 | — | — | WO | disclosed |
| WO-2009037001-A2 | NOVEL TETRAHYDROFUSEDPYRIDINES AS HISTONE DEACETYLASE INHIBITORS | 4SC AG (DE) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021771-A1 | INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC11, HDAC3 | GPR119 1302/4885GABRA1 3194/4885GABRG2 3252/4885 |
| US-20110021494-A1 | NOVEL TETRAHYDRO-FUSED PYRIDINES AS HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HDAC3 | GPR119 2402/4885GABRA1 3485/4885GABRG2 3213/4885 |
| US-20140045850-A1 | INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC11, HDAC3 | GPR119 1302/4885GABRA1 3194/4885GABRG2 3252/4885 |
| US-20120101147-A1 | INHIBITION OF HDAC2 TO PROMOTE MEMORY | HDAC2, HDAC1, HDAC3 | GPR119 1915/4885GABRA1 1410/4885GABRG2 1602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.